

May 12, 2021

Sumitomo Dainippon Pharma Co., Ltd.

Notice of Relocation of Tokyo Head Office

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that it has decided to relocate its Tokyo Head Office by the middle of 2022, as described below.

1. Relocation Destination

Tokyo Nihonbashi Tower, 2-7-1 Nihonbashi, Chuo-ku, Tokyo (11th, 12th, and 16th floors)

(Reference: Current location)

1-13-1, Kyobashi, Chuo-ku, Tokyo

2. Scheduled Date of Relocation

Middle of 2022

3. Reason for Relocation

The planned relocation destination, Tokyo Nihonbashi Tower, has large floor areas, and by consolidating the various departments, which were previously spread out over different floors, onto a single floor, a sense of unity will be fostered and the departments will work together seamlessly. In addition, the office building is a seismically isolated and damped structure, and has a high level of security, which will enhance disaster response and security measures.

With this relocation, we will strive to further improve communication and productivity by creating a more functional office that responds to diversifying work styles due to the spread of COVID-19. On top of this, the Tokyo Head Office of Sumitomo Chemical Company, Limited, our parent company, is scheduled to relocate to the same building, and we will strengthen our ties with the company more than ever.

Furthermore, the office building is directly connected to Nihonbashi Station, which is served by three subway lines, including the Toei Asakusa Line which provides direct access to both Haneda Airport and Narita Airport. We believe that this will help us build relationships with our business partners and strengthen our global business development even more.

(Reference)

Map of the new location



Tokyo Nihonbashi Tower



Contact

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: + 81-6-6203-1407 (Osaka); + 81-3-5159-3300 (Tokyo)